BG Medicine, Inc. today announced that it has entered into an agreement with Abbott Laboratories (NYSE: ABT) to extend its current development and commercialization collaboration to include the development of a galectin-3 test for Abbott Point of Care’s i-STAT^® System. Galectin-3 is a novel biomarker that may play a role in detecting the development and progression of heart failure.

Lonza has agreed to make Odyssey Thera's protein-fragment complementation assay (PCA) technology available to life science and drug discovery researchers as part of its compound-profiling services. Additionally, Odyssey Thera granted Lonza an option to certain exclusive, global technology licenses. The companies have also initiated collaborative technology, product development, and marketing activities.

The 2010 American Society for Microbiology (ASM) Gen-Probe Joseph Public Health Award is being presented to J. Michael Miller, Ph.D., D(ABMM), Associate Director for Science, National Center for Zoonotic, Vectorborne, and Enteric Diseases, Centers for Disease Control and Prevention (CDC), and Director, Microbiology Technical Services, LLC, Dunwoody, GA, for integrating microbiology into the practice of public health. This award recognizes a distinguished microbiologist who has exhibited exemplary leadership and service in the field of public health.

GlaxoSmithKline (GSK) obtained access to Regulus Therapeutics’ miR-122 antagonist patent estate as part of a potentially $150 million collaboration to develop new miRNA therapeutics against HCV and possibly other diseases. As part of the deal Regulus will receive an up-front fee along with milestone payments and royalties on worldwide product sales. Regulus aims to identify a clinical candidate during the second half of 2010 and potentially file an IND application in 2011.